Mabion specializes in the development of targeted treatments for serious diseases, using the specificity and safety of monoclonal antibodies. Their main priority drug, MabionCD20, is being developed for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis. The company covers all stages of drug development, from design to manufacturing and regulatory compliance. Mabion is also expanding its capabilities to offer contract development and manufacturing services, including the production of a COVID-19 vaccine in partnership with Novavax.